These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). Sulzbacher F; Schütze C; Burgmüller M; Vécsei-Marlovits PV; Weingessel B Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1581-1590. PubMed ID: 31037488 [TBL] [Abstract][Full Text] [Related]
11. CLINICAL FEATURES OF FLAT IRREGULAR PIGMENT EPITHELIAL DETACHMENT ASSOCIATED WITH CHOROIDAL NEOVASCULARIZATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Guo J; Tang W; Liu W; Chang Q; Xu G Retina; 2021 Jan; 41(1):199-207. PubMed ID: 32251241 [TBL] [Abstract][Full Text] [Related]
12. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes. Matušková V; Vysloužilová D; Uher M Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091 [TBL] [Abstract][Full Text] [Related]
13. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Cheng CK; Chang CK; Peng CH Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374 [TBL] [Abstract][Full Text] [Related]
14. COMPARISON OF HALVING THE IRRADIATION TIME OR THE VERTEPORFIN DOSE IN PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Shiode Y; Morizane Y; Kimura S; Hosokawa M; Kawata T; Doi S; Hosogi M; Fujiwara A; Shiraga F Retina; 2015 Dec; 35(12):2498-504. PubMed ID: 26035398 [TBL] [Abstract][Full Text] [Related]
15. CLINICAL CHARACTERISTICS AND OUTCOME OF POSTERIOR CYSTOID MACULAR DEGENERATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Mohabati D; Hoyng CB; Yzer S; Boon CJF Retina; 2020 Sep; 40(9):1742-1750. PubMed ID: 31815880 [TBL] [Abstract][Full Text] [Related]
16. Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser. Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Grzybowski A Graefes Arch Clin Exp Ophthalmol; 2017 Dec; 255(12):2299-2306. PubMed ID: 28831603 [TBL] [Abstract][Full Text] [Related]
17. PHOTODYNAMIC THERAPY FOR SYMPTOMATIC SUBFOVEAL RETINAL PIGMENT EPITHELIAL DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: Outcomes and Prognostic Factors. Hwang S; Kang SW; Kim SJ; Jang JW; Kim KT Retina; 2019 Jun; 39(6):1117-1124. PubMed ID: 29517581 [TBL] [Abstract][Full Text] [Related]
18. SEROUS MACULAR DETACHMENT IN BEST DISEASE: A Masquerade Syndrome. Zatreanu L; Freund KB; Leong BCS; Yu HG; Teke MY; Yzer S; Sadda SR; Sarraf D Retina; 2020 Aug; 40(8):1456-1470. PubMed ID: 31613838 [TBL] [Abstract][Full Text] [Related]
19. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630 [TBL] [Abstract][Full Text] [Related]